The JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY(ISSN: 1710-6222) will consider for publication original research papers (clinical or epidemiological), review articles and case reports on all aspects of clinical pharmacology and therapeutics. Editorials/Commentaries or Letters to the Editor on ethical, policy or other contemporary issues are welcomed. Authors submitting adverse event reports for publications are requested to follow the guidelines developed by Kelly et al. Adverse Event Guidelines http://www.pharmacoepi.org/pub/1c2a2a00-2354-d714-51a7-1b28777098e8
Manuscripts are received with the understanding that they are submitted solely to the Journal of Population Therapeutics and Clinical Pharmacology, and that none of the material contained in the manuscript has been published previously or is under consideration for publication elsewhere, excluding abstracts. The publisher reserves copyright on all published material, and material may not be reproduced without the written permission of the publisher. Statements and opinions are the responsibility of the authors.
TRANSFER OF COPYRIGHT FORMS: All authors are required to sign, complete, and upload the form with all new online submissions to the journal (see Journal Sections on the right side main menu panel to select the appropriate copyright form for your submission).
Author Processing Fees
Please note that starting August 1, 2016 the Journal of Population Therapeutics and Pharmacology (JPTCP) will charge an Author Processing Fee (APF) of US $750. Articles will go through a thorough peer review process, benefit from high quality editing, and will be posted on-line for greater exposure, within 60 days of acceptance. Articles are archived on the journal web site and through Portico. All articles will also be included in PubMed data base, Thompson Reuters Emerging Sources Citation Index and Scopus.
INSTRUCTIONS TO AUTHORS: Journal of Population Therapeutics and Clinical Pharmacology and Fetal Alcohol Research
Note: For specific guideline submissions to Fetal Alcohol Research - please refer to the Journal Section "FAR" on website on the homepage.
MANUSCRIPT PREPARATION:strong> Arrange the manuscript as follows: title page, structured abstract and key words, introduction, methods, results, discussion, acknowledgments, references, figure legends, tables and figures. Number the pages consecutively, beginning with the title page as 1. The last name of the first author should be typed at the top of each page. The text portion of the manuscript from title page to references should be in one electronic editable file (not as a PDF file), and the figure legends, tables and figures in a separate online file.
TITLE PAGE: Include the title, authors' names (including full first name and middle initial, do not include degrees) and the author's institutional affiliations. Under a heading of 'Corresponding Author' provide the full name, exact mailing address with postal code, telephone and fax numbers, and e-mail address of the author to whom communication and proofs should be sent.
STRUCTURED ABSTRACT: On a separate page provide a structured abstract of no more than 250 words organized under the following headings: Background, Objectives, Methods, Results and Conclusions. Further details on structured abstracts appear below. Abstracts for Editorials/Commentaries and Case Reports are required but need not be structured and should be limited to 150 words.
WORDS: At the end of the abstract, include a list of two to six key words and subjects for indexing purposes.
TEXT: Text files should be double spaced and submitted as Word(.doc) file.
HEADINGS/SUBHEADINGS: Please provide methods, results and discussion sections. References, figures and tables should be cited in the text with numbers assigned according to the order of mention in the text. Brief acknowledgments may appear at the end of the text, before the references.
FONT: Preferred font "Times New Roman". The font size should be 12 point. Set paper size in Word Page Setup at 8.5 x 11 inches (not A4).
SYMBOLS AND ABBREVIATIONS: Use only standard abbreviations; the use of non-standard abbreviations can be extremely confusing to readers. Avoid abbreviations in the title. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement. See list of NCBI Standard Acronyms and Abbreviations.
ACKNOWLEDGMENTS AND FUNDING: Individuals who contributed significantly to the research or preparation of the manuscript may be acknowledged in this section, in italics. When this is done, a cover letter can indicate that all those named have given their permission. Provide information concerning grants, contracts and other forms of financial support and the name(s) of the institution(s)at which the work originated.
REFERENCES: Personal communications, manuscripts in preparation and other unpublished data are not cited in the reference list but may be mentioned in the text in parentheses. Identify references in the text by Arabic numerals in suprascript on the line. References should be typed, double-spaced, separate from the text and numbered consecutively in the order in which they are mentioned in the text. (References cited in figures and tables, but not in the text, should be numbered consecutively following the text references.)
Please do NOT format references as 'endnotes' in the main document.
Journal references should contain inclusive page numbers; book references specific page numbers; and website references the author's name, title of document, uniform resource locator and date of access (references to other types of electronic documents should include format of the document). Indicate abstracts by the abbreviation 'Abst', and letters by 'Lett' in parentheses. Abbreviations of journals should conform to those used in Index Medicus, National Library of Medicine. The style and punctuation of references are as follows:
Periodicals: List all authors if six or fewer; otherwise list first three and add 'et al'. Do not use periods after authors' initials.
12. Piafsky KM, Sitar DS, Rangno RE, et al. Theophylline disposition with hepatic cirrhosis. N Engl J Med 1977;296:1495-7.
Books - Example: 14. Prober CG, Gold R. Antimicrobial Therapy in Infants and Children. New York: Marcel Dekker, 1993.
Chapter in book - Example: 21. Richer M, LeBel M. Pharmacokinetics of fluoroquinolones in selected populations. In: Hooper DC, ed. Quinolone Antimicrobial Agents. Washington: ASM Publications, 1993:225-244.
Website - Example:
National Library of Medicine. Images from the History of Medicine.(May 1, 1997) http://wwwihm.nlm.nih.gov/ (accessed on: January 5, 1999).
FIGURE LEGENDS: Type double-spaced, separate from the text, with figure numbers corresponding to the order in which figures are presented in the text. Identify all abbreviations appearing on figures in alphabetical order at the end of each legend. Enough information should be given to allow interpretation of the figure without reference to the text. Written permission must be obtained from the publisher to reproduce any previously published figures. Cite the source of the figure in the legend. Figure legends should not appear on the actual figures.
TABLES: Type double-spaced on separate sheets with the table number above the table and explanatory notes below. Table numbers should appear in Arabic numerals and should correspond to the order of the tables in the text. Footnote each table with an alphabetical listing of all abbreviations used. Ensure that tables are self-explanatory and that the data are not duplicated in the text. Written permission from the publisher to reproduce any previously published tables must be included. Tables must be in an editable format and not a pdf.
FIGURES: All figures must be submitted as separate editable files online electronically (not as pdfs) as Word documents or powerpoint files. The lettering on the figures should be sufficiently large to withstand reduction. Decimals, lines and other details must be bold enough for reproduction. Figures are limited to the number necessary for clarity.
CONFLICT OF INTEREST GUIDELINES: Sources of funding should be acknowledged, and all authors must disclose any commercial associations or other arrangements (e.g., financial compensation, potential to profit, consultancy, stock ownership, honoraria, patent-licensing arrangement, etc.) that might pose a conflict of interest in connection with the submitted article. Some or all of this information will be made available to the reviewers and, at the discretion of the editor, may be published in a footnote to the article.
ABSTRACTS: Abstracts should be structured (as illustrated below) and no more than 250 words for major articles (including review articles). Abstracts for case reports need not be structured, but are limited to 150 words. The abstract should be substantive rather than purely descriptive. Abbreviate only standard units of measurement. Tables, photos and figures will NOT be included as part of an abstract.
Title: The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels
Author: Ali F, Laurin M-Y, Larivire C, Tremblay D, Cloutier D
Background: Dyslipidemias are a modifiable risk factor for coronary heart disease. The benefits of cholesterol reduction drug therapies are limited by poor patient compliance with drug regimens.
Objectives: To determine the impact of a community pharmacist pilot disease-management program on patient compliance with lipid-lowering drug therapy and on serum cholesterol levels.
vMethods: One hundred forty-nine patients who were nonadherent to prescribed hypolipidemic drug regimens were recruited for this six-month prospective study. Each subject served as their own control. Pharmacists educated these patients on lipid disorders, the benefit of medication compliance and lifestyle modifications that reduce the risk for coronary heart disease. Pharmacists followed up participants by telephone at two-month intervals. Drug renewal rates were monitored throughout the study and plasma lipid levels were measured at study outset and study end.
Results: Pharmacist intervention and patient-education programs significantly increased medication compliance, as shown by a 15.3% increase (P>0.05) in the number of compliant patients and an 11 day (P>0.001) reduction in the average number of days to prescription renewal. Concurrently, levels of total cholesterol, triglycerides and low-density lipoprotein (LDL) cholesterol, were reduced by 6%, 16.2%, and 8.5% (P>0.001, 0.01, 0.01), respectively. High density lipoprotein (HDL) cholesterol remained relatively unchanged (+0.7%) so that the LDL to HDL ratio was improved by 7.2% overall (P>0.01). Almost all of the patients (99.2%) were satisfied with the program and expressed a willingness to pay an average $34.50 per 30 min consultation for the pharmacist services offered.
Conclusion: Pharmacists can contribute significantly to disease management of dyslipidemic individuals.
Key Words: Compliance, disease management, lipid-lowering therapy
Submit your manuscript Make a Submission